Late-life gene therapy extends mouse lifespan by 20 percent
A single injection of a gene therapy targeting muscle tissue extended the median lifespan of male mice by twenty percent. Their health across multiple markers also improved. The results are striking, but the therapy is far from ready for human use.
The therapy uses a virus as a delivery vehicle to introduce the gene for the protein FGF21 into muscle cells. FGF21 is a growth factor involved in metabolism and insulin sensitivity. Mice that received the therapy in later life showed increased survival and improved health markers on several measures. The researchers published these findings, summarised in the Rejuvenation Roundup by Lifespan.io.
Muscle as a delivery platform
Choosing muscle tissue as the target for this gene therapy is a strategic decision. Muscles are relatively accessible to viral delivery systems and can produce large quantities of protein. By having muscle cells produce FGF21 locally, the protein is gradually released into the bloodstream, where it can exert metabolic effects.
Using viral vectors (virus-like particles that transport genetic material) for gene therapy is an established principle. The innovation here lies in using muscle as the production site: muscles are stable, long-lived tissue that can sustain protein production over time.
Promising results, uncertain translation
A twenty percent increase in median lifespan in mice is a substantial effect. But mouse studies rarely translate directly to humans, particularly in gene therapy. Long-term safety, correct dosing, and whether the approach shows a comparable profile in people all remain open questions.
FGF21 has been on the longevity science radar for some time. The protein has also been linked to longer lifespan in certain animal species. Whether it represents a realistic target for human interventions remains an open question.
Want to research this yourself?
Search for example:
- FGF21 gene therapy lifespan
- viral vector muscle tissue
- growth factor metabolism ageing